Exact Sciences(US:EXAS) Benzingaยท2025-05-02 13:18Core Insights - Exact Sciences Corp reported a first-quarter 2025 EPS loss of 21 cents, an improvement from a 37-cent loss a year ago, and better than the analyst consensus loss estimate of 38 cents [1] - Quarterly sales reached $706.78 million, reflecting an 11% year-over-year increase, surpassing the consensus estimate of $688.64 million [1] - Screening revenue was $540 million, up 14%, while Precision Oncology revenue was $166.8 million, increasing by 2% or 4% on a core revenue basis [1] Financial Guidance - The company raised its fiscal 2025 sales guidance from $3.02 billion-$3.08 billion to $3.07 billion-$3.12 billion, compared to the consensus of $3.06 billion [2] - Screening sales are forecasted to be $2.39 billion-$2.43 billion, up from previous guidance of $2.35 billion-$2.39 billion [3] - Precision Oncology sales are expected to be $680 million-$695 million, compared to prior guidance of $675 million-$695 million [3] - Adjusted EBITDA for 2025 is projected at $425 million-$455 million, an increase from previous guidance of $410 million-$440 million [3] Market Sentiment - Analysts view the first quarter results positively, indicating that Exact Sciences is well-positioned for modest upside throughout the year [4] - The update supports a bullish thesis that could drive the stock higher, with shares trading at a forward revenue multiple of 3.5 times, suggesting room for multiple expansion [5] - Following the news, EXAS stock rose by 11.3% to $52.50 during the premarket session [5]